Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure

L. A. Siegel, E. Keung, S. J. Siskind, Robert Forman, H. Feinberg, J. Strom, D. Efstathakis, E. H. Sonnenblick, T. H. LeJemtel

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The effects of combined administration of low-dose amrinone (100 mg) and hydralazine (75-100 mg) on resting hemodynamics and exercise capacity were studied in nine patients with severe congestive heart failure. Five patients were in New York Heart Association (NYHA) functional class IV and four were in class III. Cardiac index increased from 1.92 ± 0.36 l/min/m 2 (mean ± SD) to 3.23 ± 0.63 l/min/m 2 (p < 0.001); pulmonary wedge pressure decreased from 23.6 ± 4.1 to 15.1 ± 4.7 mm Hg (p < 0.001) and systemic vascular resistance from 1666 ± 210 to 1063 ± 189 dyn-sec-cm -5 (p < 0.001). Mean arterial pressure and heart rate were not significantly changed. The onset of action ranged from 30-150 minutes and the duration of action from 4-6 hours after oral administration. When compared with amrinone alone (100 mg) or hydralazine alone (75-100 mg), the increase in stroke volume index and the decrease in pulmonary wedge pressure induced by the combined therapy were significantly greater (p < 0.01). The hemodynamics benefits at rest were associated with an improvement in NYHA functional class in all but one patient during chronic therapy. Exercise capacity (Naughton protocol) increased during the first week of therapy from 6.1 ± 4.3 to 10.6 ± 5.3 minutes (p < 0.01). This increase in exercise capacity was sustained or further improved at 3 weeks. Thus, the hemodynamic effects of low-dose amrinone can be amplified by simultaneous administration of a vasodilator such as hydralazine in patients with severe congestive heart failure. This combined therapy results in a substantial and sustained improvement in functional class and exercise capacity.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalCirculation
Volume63
Issue number4
StatePublished - 1981
Externally publishedYes

Fingerprint

Amrinone
Hydralazine
Heart Failure
Hemodynamics
Exercise
Pulmonary Wedge Pressure
Therapeutics
Vasodilator Agents
Vascular Resistance
Stroke Volume
Oral Administration
Arterial Pressure
Heart Rate

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Siegel, L. A., Keung, E., Siskind, S. J., Forman, R., Feinberg, H., Strom, J., ... LeJemtel, T. H. (1981). Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. Circulation, 63(4), 838-844.

Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. / Siegel, L. A.; Keung, E.; Siskind, S. J.; Forman, Robert; Feinberg, H.; Strom, J.; Efstathakis, D.; Sonnenblick, E. H.; LeJemtel, T. H.

In: Circulation, Vol. 63, No. 4, 1981, p. 838-844.

Research output: Contribution to journalArticle

Siegel, LA, Keung, E, Siskind, SJ, Forman, R, Feinberg, H, Strom, J, Efstathakis, D, Sonnenblick, EH & LeJemtel, TH 1981, 'Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure', Circulation, vol. 63, no. 4, pp. 838-844.
Siegel, L. A. ; Keung, E. ; Siskind, S. J. ; Forman, Robert ; Feinberg, H. ; Strom, J. ; Efstathakis, D. ; Sonnenblick, E. H. ; LeJemtel, T. H. / Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. In: Circulation. 1981 ; Vol. 63, No. 4. pp. 838-844.
@article{d20ca06364434218a382443b683c67a8,
title = "Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure",
abstract = "The effects of combined administration of low-dose amrinone (100 mg) and hydralazine (75-100 mg) on resting hemodynamics and exercise capacity were studied in nine patients with severe congestive heart failure. Five patients were in New York Heart Association (NYHA) functional class IV and four were in class III. Cardiac index increased from 1.92 ± 0.36 l/min/m 2 (mean ± SD) to 3.23 ± 0.63 l/min/m 2 (p < 0.001); pulmonary wedge pressure decreased from 23.6 ± 4.1 to 15.1 ± 4.7 mm Hg (p < 0.001) and systemic vascular resistance from 1666 ± 210 to 1063 ± 189 dyn-sec-cm -5 (p < 0.001). Mean arterial pressure and heart rate were not significantly changed. The onset of action ranged from 30-150 minutes and the duration of action from 4-6 hours after oral administration. When compared with amrinone alone (100 mg) or hydralazine alone (75-100 mg), the increase in stroke volume index and the decrease in pulmonary wedge pressure induced by the combined therapy were significantly greater (p < 0.01). The hemodynamics benefits at rest were associated with an improvement in NYHA functional class in all but one patient during chronic therapy. Exercise capacity (Naughton protocol) increased during the first week of therapy from 6.1 ± 4.3 to 10.6 ± 5.3 minutes (p < 0.01). This increase in exercise capacity was sustained or further improved at 3 weeks. Thus, the hemodynamic effects of low-dose amrinone can be amplified by simultaneous administration of a vasodilator such as hydralazine in patients with severe congestive heart failure. This combined therapy results in a substantial and sustained improvement in functional class and exercise capacity.",
author = "Siegel, {L. A.} and E. Keung and Siskind, {S. J.} and Robert Forman and H. Feinberg and J. Strom and D. Efstathakis and Sonnenblick, {E. H.} and LeJemtel, {T. H.}",
year = "1981",
language = "English (US)",
volume = "63",
pages = "838--844",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure

AU - Siegel, L. A.

AU - Keung, E.

AU - Siskind, S. J.

AU - Forman, Robert

AU - Feinberg, H.

AU - Strom, J.

AU - Efstathakis, D.

AU - Sonnenblick, E. H.

AU - LeJemtel, T. H.

PY - 1981

Y1 - 1981

N2 - The effects of combined administration of low-dose amrinone (100 mg) and hydralazine (75-100 mg) on resting hemodynamics and exercise capacity were studied in nine patients with severe congestive heart failure. Five patients were in New York Heart Association (NYHA) functional class IV and four were in class III. Cardiac index increased from 1.92 ± 0.36 l/min/m 2 (mean ± SD) to 3.23 ± 0.63 l/min/m 2 (p < 0.001); pulmonary wedge pressure decreased from 23.6 ± 4.1 to 15.1 ± 4.7 mm Hg (p < 0.001) and systemic vascular resistance from 1666 ± 210 to 1063 ± 189 dyn-sec-cm -5 (p < 0.001). Mean arterial pressure and heart rate were not significantly changed. The onset of action ranged from 30-150 minutes and the duration of action from 4-6 hours after oral administration. When compared with amrinone alone (100 mg) or hydralazine alone (75-100 mg), the increase in stroke volume index and the decrease in pulmonary wedge pressure induced by the combined therapy were significantly greater (p < 0.01). The hemodynamics benefits at rest were associated with an improvement in NYHA functional class in all but one patient during chronic therapy. Exercise capacity (Naughton protocol) increased during the first week of therapy from 6.1 ± 4.3 to 10.6 ± 5.3 minutes (p < 0.01). This increase in exercise capacity was sustained or further improved at 3 weeks. Thus, the hemodynamic effects of low-dose amrinone can be amplified by simultaneous administration of a vasodilator such as hydralazine in patients with severe congestive heart failure. This combined therapy results in a substantial and sustained improvement in functional class and exercise capacity.

AB - The effects of combined administration of low-dose amrinone (100 mg) and hydralazine (75-100 mg) on resting hemodynamics and exercise capacity were studied in nine patients with severe congestive heart failure. Five patients were in New York Heart Association (NYHA) functional class IV and four were in class III. Cardiac index increased from 1.92 ± 0.36 l/min/m 2 (mean ± SD) to 3.23 ± 0.63 l/min/m 2 (p < 0.001); pulmonary wedge pressure decreased from 23.6 ± 4.1 to 15.1 ± 4.7 mm Hg (p < 0.001) and systemic vascular resistance from 1666 ± 210 to 1063 ± 189 dyn-sec-cm -5 (p < 0.001). Mean arterial pressure and heart rate were not significantly changed. The onset of action ranged from 30-150 minutes and the duration of action from 4-6 hours after oral administration. When compared with amrinone alone (100 mg) or hydralazine alone (75-100 mg), the increase in stroke volume index and the decrease in pulmonary wedge pressure induced by the combined therapy were significantly greater (p < 0.01). The hemodynamics benefits at rest were associated with an improvement in NYHA functional class in all but one patient during chronic therapy. Exercise capacity (Naughton protocol) increased during the first week of therapy from 6.1 ± 4.3 to 10.6 ± 5.3 minutes (p < 0.01). This increase in exercise capacity was sustained or further improved at 3 weeks. Thus, the hemodynamic effects of low-dose amrinone can be amplified by simultaneous administration of a vasodilator such as hydralazine in patients with severe congestive heart failure. This combined therapy results in a substantial and sustained improvement in functional class and exercise capacity.

UR - http://www.scopus.com/inward/record.url?scp=0019505063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019505063&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 838

EP - 844

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -